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Summary
The abundant extracellular matrix of articular cartilage has to be maintained by a limited number of chondrocytes. Vice versa, the
extracellular matrix has an important role in the regulation of chondrocyte function.
Objective: In this review we discuss the role of the extracellular matrix in the regulation of chondrocyte function and the relevance for
cartilage tissue engineering. To reach this goal the international literature on this subject has been searched with a major focus on the last
5 years.
Results: Structural matrix macromolecules (e.g. collagen, hyaluronate), but also growth factors (e.g. IGF-I, TGF ) entrapped in the matrix
and released under specific conditions affect chondrocyte behavior. These factors communicate with the chondrocyte via specific membrane
receptors. In this way there is a close interaction between the extracellular and intracellular milieu. Articular cartilage has a limited capacity
of intrinsic repair, which has resulted in the development of tissue engineering approaches to repair damaged cartilage. Successful
application of scaffolds has to take into account the important role of both soluble and insoluble matrix-derived factors in cartilage
homeostasis.
Conclusion: Functional tissue engineering will only be realized when the scaffolds used will provide cartilage cells with the correct
extracellular signals. © 2002 Published by Elsevier Science Ltd on behalf of OsteoArthritis Research Society International
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Articular cartilage is a tissue with a remarkable durability.
However, trauma and abnormal joint loading may induce
localized cartilage damage. At short term this will lead to
pain, joint dysfunction and effusions. Later on localized
lesions may result in progressive, more generalized
cartilage destruction and to gross deformation of the joint.
To induce cartilage healing the use biological scaffolds with
or without cells has gained great attention. However, to be
able to rebuild the articular cartilage matrix one has to take
into account the subtle interaction between the chondro-
cytes and their surroundings. Therefore the focus of this
paper will be on the interaction between chondrocytes,
extracellular matrix and growth factors and the relevance of
these interactions for cartilage tissue engineering. Articular
cartilage consists of sparsely distributed chondrocytes sur-
rounded by extracellular matrix. The chondrocytes are
responsible for the maintenance of the articular cartilage as
a functioning entity. The extracellular matrix can be divided
in the pericellular, territorial and interterritorial compart-631ments, going from near to further removed from the cells.
Based on dry weight, the main constituents of articular
cartilage are type II collagen and the proteoglycan aggre-
can. Other components, however, are equally important on
a molar base. Moreover, the various compartments of the
extracellular matrix differ in their composition of matrix
molecules. To maintain cartilage homeostasis, the chondro-
cytes have to sense changes in matrix composition to
compensate for those changes. The feedback of the matrix
to the chondrocytes can be carried out by a direct inter-
action of the matrix component with the chondrocyt, or
by soluble factors released after matrix damage. To reach
the goal of repairing damaged articular cartilage using
(semi)artificial scaffolds, those scaffolds have to provide the
necessary signals, both soluble and insoluble, for rebuild-
ing functional articular cartilage by the chondrocytes.Received 10 January 2002; revision requested 13 February
2002; revision received 5 March 2002; accepted 11 March 2002.
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Chondrocyte proliferation, differentiation and homeo-
stasis is not only governed by soluble mediators in inter-
action with the genetic make up of these cells but also the
ECM provides important signals for chondrocyte behavior.
The interaction between chondrocytes and ECM is medi-
ated in part by a family of ECM molecule receptors called
integrins. The integrins are transmembrane receptors com-
posed of a  subunit and  subunit. Until now 15 and 8
subunits have been identified which pair in a multitude of
variations resulting in large number of dissimilar integrins.
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others bind with several different ECM proteins. The cyto-
plasmatic domain of the integrins is connected with the
cytoskeleton. The signaling of integrins is transmitted in two
directions, ‘inside-out’ such that the extracellular domain of
the integrins becomes more adhesive for their ligands and
‘outside-in’, whereby binding of integrins to their ligand
results in cellular activation1. Since cellular behavior is
strongly influenced by signals from the ECM it is crucial that
artificial scaffolds provide the adequate signals to embed-
ded or invading cells to induce or maintain these cells in
their desired differentiation stage.Chondrocytes have been
reported to express several integrins. Receptors have been
detected for type II and type VI collagen (11, 21,
111), vitronectin and osteopontin (V3), laminin (61)
and most abundantly for fibronectin (51)2–4. Remarkably,
in cartilage integrins have not only been found in the cell
membrane but also in the ECM itself5. In the cartilage
matrix 1, 1 and 51 are detected by fluorescence,
electron microscopy and immunoprecipitation. These
integrins could play a role in the development and structural
organization of the cartilage matrix.The most abundant
integrin detected on chondrocytes is the fibronectin recep-
tor 51. Isolated chondrocytes cultured in monolayer
undergo dedifferentiation to a fibroblast-like phenotype and
show an increased 51 expression6,7. This might be
related to the cell attachment on plastic or serum proteins
present in the culture medium. Binding of chondrocytes to
collagen, amongst others by 11, 21 and 101
integrins, has been shown to be essential for chondrocyte
survival9–11. Deprivation of chondrocytes from collagen
derived signals induces apoptosis10. Moreover, the inter-
action of chondrocytes with osteopontin via V3
protects articular cartilage against interleukin-1-mediated
damage11.
Besides the integrins, chondrocytes express other trans-
membrane molecules that function as receptors for ECM
molecules. Annexins, mainly chondrocyte annexin V
(anchorin II), is a type II collagen-binding molecule mainly
expressed by superficial chondrocytes12,13. Antibodies
against annexin V inhibited binding of chondrocytes to type
II collagen13. However, it is unclear if chondrocyte annexin
V has a function in the regulation of chondrocyte homeo-
stasis. Another well-studied membrane receptor for ECM
molecules is the hyaluronan receptor CD4414. CD44 has a
domain which is structurally similar to the hyaluronan
binding site of aggrecan and cartilage link protein. Binding
of chondrocytes to hyaluronan by the CD44 receptor affects
chondrocyte functioning and is essential for cartilage
homeostasis15. Blocking of CD44 hyaluronan binding on
chondrocytes results in degradation of the cartilage
matrix15.Binding Protein (LTBP18,19). In growth plate chondrocytes it
has been shown that storage of TGF  by LTBP is cell
maturation-dependent18,19. LTBP has a function in direct-
ing to and storage of TGF  in the extracellular matrix and
appears to be co-localized in the extracellular matrix with
fibrillin20.
The ECM proteoglycans decorin, biglycan and fibro-
modulin regulate TGF  activity by sequestering of TGF 
within the ECM21. The interactions of these small proteo-
glycans with TGF  are not primarily mediated by the
proteoglycan glycosaminoglycan chains but depend on the
core protein. The decorin-like proteoglycans function as
physiological regulators of TGF . Both inhibition and
stimulation of TGF  activity after binding to these small
proteoglycans has been reported22–25. For example, bind-
ing of TGF  to TGF  receptors on osteoblastic MC3T3-E1
cells was enhanced by decorin23. However, in osteo-
sarcoma cells addition of TGF  prevented TGF -mediated
up-regulation of biglycan synthesis24. Adenoviral over-
expression of decorin has been shown to prevent TGF 1
induced inhibition of lung morphogenesis26. Decorin is
bound to collagen in the ECM. Also type II collagen itself
has been shown to affect TGF  effects on cells. The
response of chondrocytes to TGF  was enhanced by
non-denatured type II collagen while heat-inactivated type
II collagen had no effects27,28. Moreover, TGF  expression
was increased by incorporation of type II collagen into
the cell culture29. These data show that typical ECM
molecules, like the small interstitial proteoglycans and type
II collagen, can affect the effect of TGF  on chondrocyte
behavior. Insulin-like growth Factor-I (IGF-I) is considered
to be the main anabolic growth factor of normal carti-
lage30,31. The biological function of IGF-I is modulated by
the interaction with the IGF-binding proteins (IGFBPs). Six
IGFBPs, designated IGFBP-1 to IGFBP-6, are known
today. In cartilage IGFBP-2 and -3 and -6 are detected but
the role of these binding proteins in this tissue is not
clear32,33. However, since IGF analogs without affinity for
the binding proteins are more potent than the natural
peptide, an inhibitory role of the IGFBPs in cartilage seems
likely33. IGFBP-3 accumulates with increasing age in the
territorial matrix of articular chondrocytes where it
co-localizes with fibronectin34. Co-presentation of IGFBP-3
with fibronectin increased the inhibitory activity of IGFBP-
334. IGF-I appears to be stored in the chondrocyte territorial
matrix through binding with IGFBP-3. Binding of IGF to
cartilage IGFBPs regulates the transport and availability of
IGF-I to the chondrocytes35. Other growth factors known to
be important in cartilage homeostasis and pathology such
as the Bone Morphogenetic Proteins (BMPs) are also
sequestered within the ECM. BMP-2 contains a heparin-
binding site in the N-terminal region36. Binding of BMP-2 to
immobilized heparin modulates the biological activity of
BMP-2. Important for articular cartilage is the binding of
BMP-2 to type IIA procollagen. The cartilage specific type II
collagen is expressed in two splice forms, IIA and IIB. Type
IIA contains an additional 69 amino acids and is synthe-
sized by chondrocyte precursors37. BMP-2 binds with type
IIA procollagen but not with IIB procollagen. This points out
to a role for type IIA procollagen during chondrogenesis by
modulation of BMP availability. Fibroblast Growth Factors
(FGFs) are small polypeptide factors most of which bind to
heparan proteoglycans of the ECM. The FGFs bind specific
receptors in the context of the heparan proteoglycans,
which results in cellular activation38–40. Perlecan, a
heparan sulfate proteoglycan, is highly expressed in carti-
lage and augments the FGF-mediated receptor activationArticular cartilage ECM and growth factors
Molecules from the extracellular matrix not only regulate
cellular behavior by providing signals to the embedded
cells through binding of integrins or other ECM receptors,
but also by binding, storage, release and presentation of
soluble mediators. Transforming growth factor  is very
abundant in articular cartilage16. In most cell types TGF  is
produced in a latent form in which the mature peptide is
complexed to the so-called Latency Associated Peptide
(LAP17). Chondrocytes, and several other cell types, pro-
duce TGF  as a high molecular weight macromulecule in
association of the latent homodimer with Latent TGF 
Osteoarthritis and Cartilage Vol. 10, No. 8 633on cells expressing this proteoglycan by augmentation of
FGF receptor binding41. Targeted disruption of the gene
encoding perlecan in mice results in severe disorganization
of the cartilage matrix42.Interaction of integrins and growth factors
The ECM itself, as well as free and ECM-bound media-
tors, regulates cartilage homeostasis. However, these
factors do not operate alone but there also appears to be
an important interplay between ECM molecules and solu-
ble mediators on the intracellular level. Binding of chondro-
cyte integrins to ECM molecules, such as fibronectin,
results in the intracellular formation of focal adhesion
plaques. The formation of these focal adhesion plaques is a
prerequisite for articular chondrocytes to be responsive to
growth factors such as FGF and IGF-I43,44. Cell adhesion
via integrin ligation regulates activation of growth factor
receptors45. These observations show a mutual depen-
dence between chondrocyte adhesion to the ECM and the
regulation of chondrocyte behavior by growth factors. This
indicates that in the development of new scaffolds for tissue
engineering, cells should not only be provided with the
correct three-dimensional architecture but also with the
adequate signals from both the ECM and growth factors. If
these signals are not initially provided to the cells by the
scaffolds, cartilage regeneration will not be obtained. Dur-
ing the course of the restoration process it can be expected
that the chondrocytes themselves will generate the
neccesary signals for further cartilage regeneration and
homeostasis.Development of tissue engineered cartilage
Since articular cartilage is a relatively uncomplicated
tissue judged on the limited cell diversity, absence of
vascularity and innervation, the development of in vitro
engineered cartilage has been attempted in the early days
of tissue engineering. However, although cartilage has a
relatively simple structure it is a dynamic tissue with char-
acteristics that contradict this tissue as an ideal model for
tissue engineering. The extracellular matrix of this tissue
has to be maintained by the scarcely distributed chondro-
cytes, asking for a great demand on the anabolic capacity
of these cells. The poor intrinsic repair capacity of articular
cartilage restricts the process of cartilage tissue formation
compared with tissue with a strong inherent repair
response, such as liver. Also the high biomechanical
demands on this tissue when placed in situ is a great
challenge for cartilage tissue engineering. Ideally, tissue
engineered cartilage has a similar structure, biochemical
composition, mechanical properties and capacity of
self-maintenance as healthy native articular cartilage.CHONDROCYTE AVAILABILITY
The development of tissue engineered cartilage in vitro,
based on (semi)artificial matrices in combination with
chondrocytes or chondrocyte precursors, is hampered by
the limited availability of cells and the absence of bio-
materials, which can adequately substitute for the natural
cartilage matrix. Articular cartilage chondrocytes can be
harvested from cartilage but the limited accessibility of this
tissue, mainly because of its inherent poor repair capacity
makes (autologous) cartilage harvesting problematic.A large number of chondrocytes is needed for the
construction of clinically significant implants. This has
resulted in the search for alternative sources for articular
chondrocytes and the application of (mesenchymal) stem
cells appears to be a logical alternative.
Autologous bone marrow can be a suitable source for
mesenchymal stem cells. Mesenchymal stem cells are
present in bone marrow in a quantity of about 1 out of every
105 cells46. These cells can be used as chondrocyte
precursors, which will develop in fully differentiated
chondrocytes when supplied with the correct differentiation
signals from the surrounding matrix and soluble mediators.
Many years ago it was shown that mesenchymal stem cells
could be directed to the chondrocyte lineage under the
influence of bone-derived growth factors47,48. Following
this line it can be expected that (genetically modified)
embryonic stem cells will be a source of chondrocytes in
the near future.SCAFFOLDS
In addition to the search for an optimal cell source the
quest for the optimal matrix has resulted in the develop-
ment and testing of both (semi) artificial and natural
materials (scaffolds). Numerous matrices have been used
as culturing systems for articular chondrocytes. Matrices
based amongst others on polyglycolic acid, polylactic acid,
hyaluronate esters, polymerized or non-polymerized fibrin,
collagen, alginate, chitosan, calcium carbonate and combi-
nations of those compounds have been used as substrates
for in vitro cartilage tissue engineering.
Polyglycolic acid, polylactic acid and a combination of
both polymers can be used as substrate for chondrocytes
resulting in cartilage tissue after 20 weeks with a relatively
high resistance to loading49. However, toxic monomers are
shown to be derived from these resorbable polymers after
degradation50. Probably more natural substrates are
hyaluronan-based polymers. These polymers have been
evaluated to support chondrocyte and mesenchymal stem
cell-derived cartilage formation. The hyaluronan-based
scaffolds are biocompatible and seeded cells easily adhere
and proliferate on this material51,52. Another widely used
biomaterial is fibrin. Polymerized fibrin can be used as a
moldable gel and is used for the growth of chondrocytes in
vitro before implantation in vivo53. As we have experienced
in our own experiments with fibrin, the stability of the
material is limited and it can easily be degraded by the
embedded chondrocytes. Culturing of rabbit articular
chondrocytes resulted in disintegration of the fibrin matrix
after 3 days54. These results have led to the development
of methods to stabilize the fibrin matrix by increasing
fibrinolytic inhibition using aprotinin and tranexamic acid55.
An alternative method is mixing of fibrin with other matrix
materials such as alginate56. Both methods stabilize the
fibrin-chondrocyte constructs and enhance the synthesis of
cartilage-specific molecules by the embedded chondro-
cytes55,56. A more recently used biomaterial is chitosan, a
copolymer of glucosamine and N-acetylglucosamine, a
derivative of chitin57,58. Chitosan is used alone and in
combination with chondroitin sulfate. Chondrocytes
cultured on chitosan were spherical, in contrast to
spindle shaped cells cultured on plastic, and maintained
the synthesis of type II collagen and aggrecan57,58.
Scaffolds based on type I collagen have been used by
our own group. The sources of commercial type I collagen
634 P. M. van der Kraan et al.: Chondrocyte and ECM interactionsinfluenced chondrocyte behavior, probably due to contami-
nating molecules in the matrices59. Compared to chondro-
cytes cultured in alginate, chondrocytes grown in type I
collagen have a higher proliferation capacity but lose their
differentiated phenotype60. Studies in our and other groups
are continuing, using the cartilage specific type II collagen
as a substrate61. Highly purified type II collagen may be a
better matrix for chondrocyte culture than type I colla-
gen62,63. However, to provide the chondrocytes with a
matrix that provides similar signals to cells as natural
cartilage, other matrix molecules have to be incorporated in
the type II collagen matrix.
Besides the chemical properties of the matrix, other
parameters also determine the final outcome of cartilage
formation. The microtopography of the material resulting in
differences in porosity and surface roughness contributes
to the chondrocyte behavior63. Moreover, the in vitro cul-
ture conditions itself strongly modulate cartilage formation.
Incubation of chondrocytes on polymer scaffolds in rotating
vessels showed higher synthesis of cartilage specific mol-
ecules and better mechanical properties compared with
chondrocytes cultured in mixed or static flasks64,65. These
results show that the hydrodynamic culture conditions
influence the formation of functional tissue engineered
cartilage.
In vitro tissue engineering is the application of the
principles of developmental biology and tissue regenera-
tion to the in vitro situation. Since soluble factors signifi-
cantly contribute to the morphogenesis of newly formed
tissues, these factors can be used to stimulate in vitro
cartilage formation. Many studies have been performed
with cartilage explants and chondrocytes cultured in
monolayer but the number of studies applying these growth
factors to cartilage tissue engineering in vitro is limited so
far.GROWTH FACTORS
Members of the TGF  superfamily are known to play an
important role in cartilage formation during embryonic
stages and can stimulate cartilage repair in vivo66–68.
Equine chondrocytes cultured in a three-dimensional
fibrin matrix showed an increased cell proliferation and
proteoglycan synthesis in the presence of TGF . The
effect of TGF  was most pronounced in the absence of
serum in the culture medium69. TGF  stimulated proteo-
glycan synthesis in bovine articular chondrocytes cultured
in alginate and appeared to be more potent under these
conditions than BMP-270,71. Others have shown that
BMP-7 not only stimulates proteoglycan synthesis but also
synthesis of matrix molecules known to be important in
retention of the major cartilage proteoglycan aggrecan,
namely hyaluronan and CD4472.
Besides the members of the TGF  superfamily other
growth factors have been tested. IGF-I stimulates proteo-
glycan synthesis of articular chondrocytes cultured in
alginate70,71. Platelet-derived growth factor (PDGF-BB)
increased cell proliferation of bovine chondrocytes cultured
on collagen gels but production of proteoglycan was signifi-
cantly decreased under the influence of PDGF, indicating
an harmful effect of PDGF on chondrocyte differentiation73.
During expansion in monolayer, chondrocytes loose their
differentiated phenotype. Culturing of articular chondro-
cytes in monolayer in the presence of FGF-2 followed by
transfer of these cells to a three-dimensional polymer
carrier induced redifferentiation to mature chondrocytes74.This suggests that FGF can be used to increase chondro-
cyte cell number if this treatment is followed by the culturing
of the cells in a three-dimensional scaffold.
Differentiation of mesenchymal stem cells to a particular
lineage, osteoblast, adipocytes, muscle cells and chondro-
cytes, can be regulated by specific growth factors. Myo-
genic differentiation of mesenchymal stem cells is inhibited
by BMP-2 and TGF 75. Chondrogenic differentiation of
marrow-derived mesenchymal stem cells is strongly stimu-
lated by TGF  in rabbit, equine and human systems76–78.
Embryonic stem cells of murine origin can be directed to
chondrocytic differentiation by application of BMP-2 or
BMP-479.
An alternative to the addition of growth factors to the
culture medium is the incorporation of genes coding for
these growth factors in the cells itself. Introduction of IGF-1,
BMP-2 or TGF  by adenoviral transfection of articular
chondrocytes resulted in increased synthesis of matrix
molecules by these cells80. Similar findings were reported
after retroviral and non-viral transfection of, respectively,
meniscal cells or chondrocytes with TGF 81,82. The appli-
cation of gene-enhanced tissue engineering will result in
the development of cartilage grafts with the potential for
prolonged synthesis of growth factors after transfer to the in
situ lesion site. The latter might stimulate the integration of
the scaffold into the cartilage lesion when implanted in vivo.
Optimization of the regeneration of articular cartilage
should be based on knowledge of the normal function and
development of this tissue. Functional tissue engineered
cartilage can only be achieved when those matrices are
used for cartilage regeneration which provide invading or
embedded cells with the correct signals, both soluble and
insoluble, Results from other organs and tissues show that
the application of the correct differentiation signals in com-
bination with cells able to respond to these signals (e.g
embryonic stem cells) can achieve remarkable results in
the field of tissue generation and tissue engineering.References
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